Platelet Function Testing in High-risk Coronary Artery Disease Patients - An Update

Login or register to view PDF.
Abstract

Following activation and aggregation, human platelets play an important role in promoting vascular and stent thrombosis. By inhibiting platelets, aspirin and clopidogrel limit this process; used in combination they are particularly helpful when administered to patients with acute coronary syndromes undergoing percutaneous coronary intervention with stenting. Platelet function is traditionally assessed by light transmission aggregation (LTA) test in platelet-rich plasma (PRP). By using different agonists to induce aggregation, the extent of platelet inhibition can be monitored. As platelet LTA presents some drawbacks (manual sample preparation, selection of agonists and their concentration, time-consuming), new and renewed automated systems have been introduced to provide a simple, rapid assessment of platelet function, including point-of-care (POC) methods that are also suitable for use in non-specialized laboratories.

Disclosure
The author has no conflicts of interest to declare.
Correspondence
Rita Paniccia, PhD, Thrombosis Center, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni, 85 50134 Florence, Italy. E: rita.paniccia@unifi.it
Received date
06 November 2008
Accepted date
09 January 2009
Citation
US Cardiology - Volume 6 Issue 1;2009:6(1):75-80
Correspondence
Rita Paniccia, PhD, Thrombosis Center, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni, 85 50134 Florence, Italy. E: rita.paniccia@unifi.it
PREMIUM CONTENTArticles are free-to-download for registered users only. It's free to register and takes less than 1 minute. Please either Login or register to read in HTML & eJournal format or to download our PDFs. *Your details will only be used internally to learn more about our audience and will never be passed on.

Vegan Heart – The Blog of Heather Shenkman MD, FACC

  • 19 November 2014
    I had an awesome triathlon season -- three Ironman 70.3 events, moving from top 27%, to top 23%, to top 20% in my age group.After my nearly ten years...
  • 28 October 2014
    Last week, I attended the annual meeting of the American College of Lifestyle Medicine.  Not only was it an opportunity to hear some of my...

Partners